News | April 29, 2023
RPG Life Sciences posts Q4 revenue at Rs 118.49 Cr
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
The company sees the business reaching $100mn
In Q2 FY23, the overall performance of the company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
Candle Partners, an investment banking & advisory service for M&A among others, has closed many deals in the healthcare space. Ankit Poddar, Director, Candle Partners spoke to Thomas C Thottathil, Editor, Indianpharmapost.com about the prospects for the industry.
_256_384.jpg)
The deal will be financed by Rs 300 crore of internal accruals and Rs 350 crore of borrowings
Mankind Pharma has agreed to retain Panacea Biotec’s sales and marketing team engaged in this business
ICICI Direct’s analysis of Cipla’s Q3FY22 results
ICICI Direct gives a preview on the earnings narrative for Q3FY22
Subscribe To Our Newsletter & Stay Updated
